STM publisher Elsevier, Netherlands, and Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, have signed a multi-year contract. Under the deal, Elsevier will provide access to Reaxys to all Pharmaron researchers.
Reaxys will enable Pharmaron to continue to consolidate its scientific excellence and to stay competitive in drug R&D, and also ensure that Pharmaron has the best possible resources available to provide high-quality research and solutions to their customers.
Pharmaron is a key player in the Chinese CRO industry, a preferred drug R&D service provider to global pharmaceutical and chemical companies. The increased emphasis on partnership and productivity has made validated information access indispensible. Consequently access to Reaxys’ chemical information will significantly help Pharmaron continue to be a highly competitive and dynamic player in the industry.
Reaxys is a registered trademark owned and protected by Elsevier Properties SA and used under license.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
